ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ ΜΙΧΑΛΗ Β. ΚΑΡΑΜΟΥΖΗ

1 ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ ΜΙΧΑΛΗ Β. ΚΑΡΑΜΟΥΖΗ ΠΑΡΟΥΣΑ ΘΕΣΗ: Επίκουρος Καθηγητής, Εργαστήριο Βιολογικής Χημείας, Ιατρική Σχολή Πανεπιστημίου Αθηνών ΠΡΟΠΤΥΧΙΑΚΕΣ ΣΠΟΥΔΕΣ: Φοιτητής Ιατρικής Σχολής του Πανεπιστημίου Πατρών (1990-1995). ΜΕΤΑΠΤΥΧΙΑΚΕΣ ΣΠΟΥΔΕΣ: (1) Κάτοχος Μεταπτυχιακού Διπλώματος Ειδίκευσης (Master of Science) του Μεταπτυχιακού Προγράμματος Βασικών Ιατρικών Επιστημών (Φαρμακοκινητική-Τοξικολογία) Ιατρικής Σχολής Πανεπιστημίου Πατρών. Επιβλέπουσα Καθηγήτρια Κυρία Σωτηροπούλου-Μπονίκου Γεωργία, Αν. Καθηγήτρια, Εργαστήριο Ανατομίας, Ιατρική Σχολή Πανεπιστημίου Πατρών (2) Κάτοχος Διδακτορικού Διπλώματος (PhD) Ιατρικής Σχολής Πανεπιστημίου Πατρών με θέμα "Συνομιλία (cross-talk) των υποδοχέων ρετινοειδών και του μεταγραφικού παράγοντα ΑΡ-1 στην καρκινογένεση. Μοντέλο: προκαρκινικές βλάβες και καρκινώματα του λάρυγγα. Στόχος: πιθανή εφαρμογή στη χημειοπροφύλαξη". Επιβλέπουσα Καθηγήτρια Κυρία Σωτηροπούλου-Μπονίκου Γεωργία, Αν. Καθηγήτρια, Εργαστήριο Ανατομίας, Ιατρική Σχολή Πανεπιστημίου Πατρών ΠΡΟΥΠΗΡΕΣΙΑ 1) Αγροτικός Ιατρός Κ.Υ. Ερυμάνθειας (20\9\96-20\10\97). 2) Ιατρεία Μονάδων Πολεμικής Αεροπορίας (4\11\97-4\9\98). 3) Ειδικευόμενος Βοηθός στην Αιματολογική-Ογκολογική Κλινική του Παθολογικού Τομέα του 251 Γενικού Νοσοκομείου Αεροπορίας (4\9\98-4\7\99). 4) Ειδικευόμενος Παθολογίας στην Πανεπιστημιακή Παθολογική Κλινική του Περιφερικού Πανεπιστημιακού Νοσοκομείου Πάτρας (12\7\99-25\3\01). 1

2 5) Ειδικευόμενος Αιματολογίας στο Αιματολογικό Τμήμα της Πανεπιστημιακής Παθολογικής Κλινικής του Περιφερικού Πανεπιστημιακού Νοσοκομείου Πάτρας (29\6\01-15\1\02). 6) Ειδικευόμενος Παθολογικής Ογκολογίας στην Α Παθολογική Ογκολογική Κλινική του Α.Ο.Γ.Ν.Α. Ο ΑΓΙΟΣ ΣΑΒΒΑΣ (24/3/2003-24/3/2006). 7) Επιστημονικός Συνεργάτης Ογκολογικής Κλινικής Νοσοκομείου Metropolitan (15/5/2006-15/8/2006). 8) Visiting Assistant Professor, Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, USA (01/09/2006-31/08/2007). ΔΙΑΚΡΙΣΕΙΣ - ΥΠΟΤΡΟΦΙΕΣ - ΤΙΜΗΤΙΚΟΙ ΤΙΤΛΟΙ 1) Κρατική υποτροφία του Ι.Κ.Υ. (Ίδρυμα Κρατικών Υποτροφιών) στο 1 ο έτος (5 ος ), 2 ο έτος (3 ος ), και 3 ο έτος (1 ος ) φοίτησής μου στην Ιατρική Σχολή Πατρών. 2) Τιμητική Διάκριση από το Τμήμα Ιατρικής του Πανεπιστημίου Πατρών για την σειρά αποφοίτησής μου κατά το Ακαδημαϊκό έτος 1995-96 (4 ος μεταξύ 113 αποφοιτησάντων με μ.ο. 7,66). 3) 2 ο βραβείο για την παρουσίαση εργασίας στο 3 rd International Conference on Breast Imaging, Βενετία, Ιταλία, 3-6 Απριλίου, 2001. 4) Βραβείο για την παρουσίαση εργασίας στο 5 th International HSBCR Congress, Αθήνα, Ελλάδα, 1-2 Νοεμβρίου, 2001. 5) Κρατική υποτροφία του Ι.Κ.Υ. για τη σειρά αποφοίτησής μου από το Μεταπτυχιακό Πρόγραμμα Ειδίκευσης στις Βασικές Ιατρικές Επιστήμες Ιατρικής Σχολής Πανεπιστημίου Πατρών (1 ος ). 6) 1 o βραβείο αναρτημένης ανακοίνωσης στο 8 ο Πανελλήνιο Συνέδριο Μαστολογίας, Θεσσαλονίκη, Ελλάδα, 7-10 Μαρτίου, 2002. 7) Βραβείο Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών 2002 «Φωτίνειο Διαγώνισμα για την καταπολέμηση του καρκίνου» για την εργασία «M.V. Karamouzis, E. Likaki-Karatza, F.A. Mpadra, P. Ravazoula, D. Koukouras, E. Tzorakoeleptherakis, A.G. Papavassiliou & H.P. Kalofonos: "Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors", Int J Cancer, 102(1): 86-90, 2002. 2

3 8) 1 o βραβείο προφορικής ανακοίνωσης στο 12 ο Πανελλήνιο Συνέδριο Ογκολογίας, Αθήνα, Ελλάδα, 27-30 Νοεμβρίου, 2003. 9) Υποτροφία Εξωτερικού Κλινικής Ογκολογίας - Εταιρεία Ογκολόγων Παθολόγων Ελλάδας (ΕΟΠΕ) 2005-2006. ΣΥΜΜΕΤΟΧΗ ΣΕ ΔΙΕΘΝΗ ΠΡΩΤΟΚΟΛΛΑ Multicenter phase III open label randomized trial comparing CPT-11 in combination with a 5-FU/FA infusional regimen to the same 5-FU/FA infusional regimen alone as adjuvant treatment of stage III colon cancer (RP64174-V-307). ΣΥΜΜΕΤΟΧΗ ΣΕ ΕΡΕΥΝΗΤΙΚΑ ΠΡΩΤΟΚΟΛΛΑ Phase I/II trial of combined use of activated NK (Natural Killer) cells and chemotherapy as first line treatment in patients with advanced (Stage IIIB/IV) nonsmall cell lung cancer. ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΞΕΝΑ ΠΕΡΙΟΔΙΚΑ 1) S. Andrikopoulos, M. Karamouzis, G. Papachristou, A. Vagenakis & H Kalofonos: "The status of undergraduate oncology education in Medical Schools in Greece and abroad", J Cancer Educ, 14(4): 223-227, 1999. 2) H.P. Kalofonos, M.V. Karamouzis & A.A. Epenetos: "Radioimmunoscintigraphy in patients with ovarian cancer", Acta Oncol, 40(5): 549-557, 2001. 3) S. Voulgaris, M. Partheni, M. Karamouzis, P. Dimopoulos, N. Papadakis & H.P. Kalofonos: "Intratumoral doxorubicin in patients with malignant brain gliomas", Am J Clin Oncol, 25(1): 60-64, 2002. 4) A.G. Papatsoris, F.A. Mpadra & M.V. Karamouzis: "Prostatic adenocarcinoma presenting as solitary cerebellar metastasis. Case report and review of the literature", Tumori, 88(1): 61-64, 2002. 5) M.V. Karamouzis, T. Papadas, I. Varakis, G. Sotiropoulou-Bonikou & A.G. Papavassiliou: "Induction of the CBP transcriptional co-activator early during laryngeal carcinogenesis", J Cancer Res Clin Oncol, 128(3): 135-140, 2002. 6) T. Papadas, N. Charokopos, M.V. Karamouzis, C. Pierakeas, M. Symeonidi, G. Economou & P. Goumas: "Rehabilitation after laryngectomy - A practical approach and guidelines", J Cancer Educ, 17(1): 37-39, 2002. 3

4 7) M.V. Karamouzis, VG Gorgoulis, A.G. Papavassiliou: "Transcription factors and neoplasia: vistas in novel drug design", Clin Cancer Res, 8(6): 949-961, 2002. 8) M.V. Karamouzis, E. Likaki-Karatza, F.A. Mpadra, P. Ravazoula, D. Koukouras, E. Tzorakoeleptherakis, A.G. Papavassiliou & H.P. Kalofonos: "Non-palpable breast carcinomas: correlation of mammographically detected malignantappearing microcalcifications and molecular prognostic factors", Int J Cancer, 102(1): 86-90, 2002. 9) E. Likaki-Karatza, F.A. Mpadra, M.V. Karamouzis, P. Ravazoula, D. Koukouras, S. Margariti & I. Dimopoulos: "Acute lymphoblastic leukemia (ALL) relapse in breast diagnosed with gray-level and color doppler ultrasonography", J Clin Ultr, 30(9): 552-556, 2002. 10) A.G. Papatsoris, F.A. Mpadra, M.V. Karamouzis & C.Y. Frangides: "Bruccelar orcheoepididimytis in Western Greece: ten years experience", Int J Infect Dis, 6(4): 309-313, 2002. 11) A.G. Papatsoris, F.A. Badra & M.V. Karamouzis: "Post-traumatic testicular torsion". Ulus Trauma Derg, 9(1): 70-71, 2003. 12) E.G. Solomou, G. Patriarheas, F.A. Mpadra, M.V. Karamouzis & I. Dimopoulos: "Asymptomatic adult cystic lymphangioma of the spleen: Case report and review of the literature". Magn Reson Imaging, 21: 81-84, 2003. 13) A.G. Papatsoris, F.A. Badra, M.V. Karamouzis, E. Likaki-Karatza & T. Karatzas: "Torsion of undescended testis in an adult with Down's syndrome". Int J Urology, 10: 233-235, 2003. 14) M.V. Karamouzis, M. Melachrinou, M. Fratzoglou, Ch Labropoulou-Karatza & H.P. Kalofonos: "Hepatocellular carcinoma metastasis in the pituitary gland: case report and review of the literature", J Neuro-Oncology, 63(2): 173-177, 2003. 15) M.V. Karamouzis, F.A. Badra & A.G. Papatsoris: "A case of colonic ischemia mimicking carcinoma". Int J Gastrointestinal Cancer, 32(2-3): 165-168, 2003. 16) M.V. Karamouzis, G. Sotiropoulou-Bonikou, G. Vandoros, I. Varakis & A.G. Papavassiliou: Retinoid-X-receptor alpha (RXRα) expression during laryngeal carcinogenesis: Detrimental or beneficial event?. Cancer Lett, 199(2): 175-183, 2003. 17) Α. Alexopoulos, D. Tryfonopoulos, M.V. Karamouzis, G. Gerasimidis, I. Karydas, K. Kandilis, J. Stavrakakis, H. Stavrinides, C. Georganta, A. Ardavanis & G. 4

5 Rigatos: Evidence for In Vivo Synergism between Docetaxel and Gemcitabine in Patients with Metastatic Breast Cancer. Ann Oncol, 15: 88-94, 2004. 18) M.V. Karamouzis, G. Sotiropoulou-Bonikou, G. Vandoros, I. Varakis & A.G. Papavassiliou: Differential expression of retinoic acid receptor beta (RARβ) and AP-1 transcription factor in normal, premalignant and malignant human laryngeal tissues. Eur J Cancer, 40: 761-773, 2004. 19) M.V Karamouzis & A.G. Papavassiliou: COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet?. Expert Opin Invest Drugs, 13: 359-372, 2004. 20) Α. Alexopoulos, M.V. Karamouzis, H. Stavrinides, A. Ardavanis, K. Kandilis, J. Stavrakakis, C. Georganta & G. Rigatos: Phase II study of pegylated liposomal doxorubicin (Caelyx ) and docetaxel as first line treatment in metastatic breast cancer Ann Oncol, 15: 891-895, 2004. 21) H.P. Kalofonos, D. Bafaloukos, T.G. Kourelis, M.V. Karamouzis, P. Megas, G. Iconomou, D. Dimitropoulos, P. Kosmidis & E. Lampiris: "Adriamycin and cisplatinum as first line treatment in unresectable locally advanced or metastatic adult soft tissue sarcomas". Am J Clin Oncol, 27: 307-311, 2004. 22) Α. Alexopoulos, M.V. Karamouzis & G. Rigatos: In Vivo Synergism between Docetaxel and Gemcitabine in Patients with Metastatic Breast Cancer: The general concept and the future perspectives of such a rationale approach, Semin Oncol, 31 (suppl 5): 25-30, 2004. 23) A.G. Papatsoris, A. Triantafyllidis, A. Gekas, M.V. Karamouzis & T. Rosenbaum: Leydig cell tumor of the testis. New cases and review of the current literature. Tumori, 90: 422-423, 2004. 24) M.V. Karamouzis, N. Apostolikas, Ch. Georganta, G. Lainakis, K. Kandylis & G. Rigatos: A case of relapsed CD20 (+) mixed cellularity Hodgkin s Disease treated with sequential Rituximab and Radiotherapy Am J Haematol, 77: 418-419, 2004. 25) F.A. Badra, M.V. Karamouzis, V. Zolota & V. Pastromas: A case of multi-organ Langerhan s cell histiocytosis presented with pneumothorax, Eur J Intern Med, 15: 467-469, 2004. 26) M.V. Karamouzis: The status of chemoprevention in the current cancer therapeutic armamentarium, Journal of BUON, 9: 363-372, 2004. 5

6 27) H.P. Kalofonos, C. Kourousis, M.V. Karamouzis, G. Iconomou, P. Megas & V. Georgoulias: A phase II study of docetaxel and epirubicin in advanced adult soft tissue sarcomas, Sarcoma, 4: 129-133, 2004. 28) M.V. Karamouzis & A.G. Papavassiliou: Retinoid receptors cross talk in respiratory epithelium cancer chemoprevention, Trends in Molecular Medicine, 11: 10-16, 2005. 29) A.G. Papatsoris, M.V. Karamouzis & A.G. Papavassiliou: Novel insights into the implication of the IGF-1 network in prostate cancer, Trends in Molecular Medicine, 11: 52-55, 2005. 30) Α.G. Papatsoris, M.V. Karamouzis & A.G. Papavassiliou: Novel biological agents for the treatment of hormone-refractory prostate cancer, Curr Med Chem, 12(3): 277-296, 2005. 31) M.V. Karamouzis, A. Ardavanis, A. Alexopoulos, A. Papadopoulou, N. Apostolikas & G. Rigatos: Multiple cutaneous acral metastases in a female with breast adenocarcinoma treated with pegylated liposomal doxorubicin: Incidental or etiological association?, Eur J Cancer Care, 14: 267-271, 2005. 32) A. Ardavanis, D. Tryfonopoulos, G. Orfanos, M. Karamouzis, A. Scorilas, A. Alexopoulos & G. Rigatos: Safety and Efficacy of Trastuzumab Every 3 Weeks Combined with Cytotoxic Chemotherapy in Patients with HER2-Positive Recurrent Breast Cancer: Findings from a Case Series. Onkologie, 28(11):558-564, 2005. 33) A. Ardavanis, D. Tryfonopoulos, G. Orphanos, G. Ioannidis, M. Karamouzis & G. Rigatos: First-line chemotherapy with fluorouracil-epirubicin-navelbine (FEN) combination in advanced breast cancer. Anticancer Res, 25: 4493-4498, 2005. 34) A. Ardavanis, M.V. Karamouzis, A. Alexopoulos & G. Rigatos: Simultaneous endometrioid ovarian and uterine carcinoma diagnosed after in-vitro fertilization procedure case report and review of the literature, Eur J Gynaecol Oncol, 26: 654-656, 2005. 35) G. Vandoros, P.A. Konstantinopoulos, G. Sotiropoulou-Bonikou, A. Kominea, P. Andrikopoulos, G.I. Papachristou, M.V. Karamouzis, M. Gkermpesi, I. Varakis, & A.G. Papavassiliou: PPAR-gamma is expressed and NF-KB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol, 132: 76-84, 2006. 6

7 36) F.A Badra, M.V. Karamouzis, E. Likaki-Karatza, P. Ravazoula, E. Tzorakoelepftherakis, D. Koukouras, G. Iconomou, D. Siablis, A.G. Papavassiliou & H.P. Kalofonos: Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression, Cancer Lett, 244: 34-41, 2006. 37) Μ.V. Karamouzis, A.A. Ifanti, G. Iconomou, A.G. Vagenakis & H.P. Kalofonos: Medical students views of undergraduate oncology education: A comparative study, Educ Health (Abingdon), 19: 61-70, 2006. 38) M.V. Karamouzis, P. Liodantonaki & G. Rigatos: A case of breast carcinoma late metastasis to the kidney, Am J Clin Oncol, 29:209-210, 2006. 39) A. Ardavanis, A. Scorilas, D. Tryfonopoulos, G. Orphanos, I. Missitzis, M.V. Karamouzis, M. Chrysochoou, A. Sotiropoulou, N. Arnogiannaki, G. Ioannidis, G. Pissakas, G. Rigatos: Multidisciplinary Therapy of Locally Far-Advanced or Inflammatory Breast Cancer with Fixed Perioperative Sequence of Epirubicin, Navelbine, and Fluorouracil Chemotherapy, Surgery, and Radiotherapy: Long- Term Results, The Oncologist, 11: 563-573, 2006. 40) M.V. Karamouzis & A.G. Papavassiliou: The IGF-1 network in lung carcinoma therapeutics, Trends Mol Med, 12:595-602, 2006. 41) M.V. Karamouzis, A. Fida, N. Apostolikas & G. Rigatos: A case of HER-2 (+) squamous cell breast carcinoma: an unusual presentation of an unusual clinical entity, Eur J Surg Oncol, 32:1250-1251, 2006. 42) E.G. Iliopoulou, M.V. Karamouzis, I. Missitzis, A. Ardavanis, C.N. Baxebanis, G. Rigatos, M. Papamichail, S.A. Perez: Increased frequency of CD4+ cells expressing CD161 in cancer patients, Clin Cancer Res, 12: 6901-6909, 2006. 43) M.V. Karamouzis, H. Linardou, G. Papadopoulos, E. Bousboukea, D. Kanaloupiti, M. Bitza, N. Spourlis & D. Bafaloukos: Gastrointestinal solitary metastases from lung squamous cell carcinoma, Lung Cancer, 55: 251-252, 2007. 44) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: The AP-1 Transcription Factor in Respiratory Epithelium Carcinogenesis, Mol Cancer Res, 5: 109-120, 2007. 7

8 45) A.G. Papatsoris, M.V. Karamouzis & A.G. Papavassiliou: The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics, Mol Cancer Ther, 6: 811-819, 2007. 46) P.A. Konstantinopoulos, R.J. Sullivan, M.V. Karamouzis, & B.J. Dezube: Investigational agents for treatment of AIDS-Related Kaposi Sarcoma, Expert Opin Investig Drugs, 16: 495-504, 2007. 47) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: Roles of CREB-Binding Protein (CBP)/p300 in respiratory epithelium tumourigenesis, Cell Res, 17: 324-332, 2007. 48) M.V. Karamouzis, F.A. Badra & A.G. Papavassiliou: Breast cancer: the upgraded role of HER-3 and HER-4, Int J Biochem Cell Biol, 39: 851-856, 2007. 49) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: The molecular basis of retinoids use in breast cancer chemoprevention, Cell Oncol, 29: 183-184, 2007. 50) P.A. Konstantinopoulos, M.V. Karamouzis & A.G. Papavassiliou: Focus on acetylation: of histones and beyond, from cancer and beyond, Expert Opin Investig Drugs, 16: 569-571, 2007. 51) M.V. Karamouzis, S.A. Perez, D.V. Skarlos, A. Ardavanis, N.N. Sotiriadou, E.G. Iliopoulou, M.L. Salagianni, P.A. Sotiropoulou, G. Orfanos, C.N. Baxevanis, G. Rigatos & M Papamichail: CD4+CD25+ Regulatory T Cell frequency in HER/neu positive and negative advanced stage breast cancer patients, Clin Cancer Res, 13: 2714-2721, 2007. 52) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: The role of STATs in lung carcinogenesis: an emerging target for novel therapeutics, J Mol Med, 85: 427-436, 2007. 53) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: Intriguing issues of EGFR targeting in head and neck cancer, Ann Oncol, 18: 962, 2007. 54) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: Epigenetics in respiratory epithelium carcinogenesis: prevention and therapeutic challenges, Cancer Treat Rev, 33: 284-288, 2007. 55) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: Compartmentalization of EGFR signalling might potentiate the optimal use of EGFR inhibitors in cancer therapeutics, Br J Cancer, 96: 1924-1925, 2007. 8

9 56) P.A. Konstantinopoulos, M.V. Karamouzis & A.G. Papavassiliou: Targeting post-translational modifications and functional regulation of the Ras superfamily of small G-proteins for anticancer drug development, Nat Rev Drugs Discov, 6:541-555, 2007. 57) M.V. Karamouzis, J.R. Grandis & A. Argiris: Therapies against epidermal growth factor receptor in aerodigestive carcinomas. JAMA, 298: 70-82, 2007. 58) P.A. Konstantinopoulos, M.V. Karamouzis & A.G. Papavassiliou: Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin, BBA Reviews on Cancer, 1776: 1-9, 2007. 59) M.V. Karamouzis, G. Ioannidis & G. Rigatos: Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study, Eur J Cancer Care, 16: 433-438, 2007. 60) A. Argiris, S. Agarwala, M.V. Karamouzis, L.A. Burmeister & S.E. Carty: A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer, Invest New Drugs, 2007. 61) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: Trastuzumab Mechanism of action and use in clinical practice, New Engl J Med, 357: 1664, 2007. 62) M.V. Karamouzis & A. Argiris: Update on the role of EGFR inhibitors in cancer therapeutics, Cancer Treat Res, 135: 257-275, 2007. 63) P.A. Konstantinopoulos, G.P. Vandoros, M.V. Karamouzis, M. Gkermpesi, G. Sotiropoulou-Bonikou & A.G. Papavassiliou: EGF-R is expressed and AP-1 and NF-KB are activated in stromal myofibroblasts surrounding colon adenocarcinomas paralleling expression of cyclooxygenase-2 and VEGF, Cell Oncol, 29: 477-482, 2007. 64) M.V. Karamouzis, A. Argiris & J.R. Grandis: Clinical applications of gene therapy in head and neck cancer, Curr Gene Ther, 7: 446-457, 2007. 65) P.A. Konstantinopoulos, M.V. Karamouzis, A.G. Papatsoris & A.G. Papavassiliou: Matrix metalloproteinase inhibitors as anticancer agents, Int J Biochem Cell Biol, 40: 1156-1168, 2007. 66) A. Argiris, M.V. Karamouzis, J. Johnson, D.E. Heron, D. Eibling, E. Cano, S. Urba, J, Gluckman Y. Wang & S. Agarwala: A phase III randomized trial of 9

10 postoperative radiotherapy with or without carboplatin in patients with high risk, locally advanced squamous cell carcinoma of the head and neck, Laryngoscope, 118: 444-449, 2007. 67) M.V. Karamouzis, P.A. Konstantinopoulos, F.A. Badra & A.G. Papavassiliou: SUMO and estrogen eceptors in breast cancer, Breast Cancer Res Treat, 107: 195-210, 2008. 68) P.A. Konstantinopoulos, M.V. Karamouzis & A.G. Papavassiliou: Thaizolidinediones and cardiovascular events: Is concomitant aspirin use a confounder?, JAMA, 299: 1539, 2008. 69) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: ErbB/HER receptor family in breast cancer The more we search the more we learn, Ann Oncol, 19: 1020-1021, 2008. 70) M.V. Karamouzis, A. Argiris, D. Raben & R. Ferris: Head and Neck Cancer, Lancet, 371: 1695-1709, 2008. 71) G.P. Vandoros, T. Manolidis, M.V. Karamouzis, M. Gkermpesi, M. Lambropoulou, A.G. Papatsoris, I. Zachos & P.A. Konstantinopoulos: Leiomyosarcoma of the prostate: case report and review of 54 previously published cases. Sarcoma, 2008. 72) P.A. Konstantinopoulos, M.V. Karamouzis & A.G. Papavassiliou: Educational and Social-Ethical Issues in the Pursuit of Molecular Medicine. Mol Med, 15: 60-63, 2009. 73) Zachos I, Konstantinopoulos PA, Vandoros GP, Karamouzis MV, Papatsoris AG, Podimatas T, Papachristodoulou A, Chrisofos M, Deliveliotis C, Papavassiliou AG: Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy. J Cancer Res Clin Oncol, 135: 1169-75, 2009. 74) M.V. Karamouzis, S. Moschos: Endostatin in cancer therapeutics, Expert Opin Biol Ther, 9: 641-648, 2009. 75) D.E. Heron, R.L. Ferris, M.V. Karamouzis, R.S. Andrade, E.L. Deeb, S. Burton, W.E. Gooding, B.F. Branstetter, J.M. Mountz, J.T. Johnson, A. Argiris, J.R. Grandis, S.Y. Lai: Stereotactic Body Radiotherapy for Recurrent Squamous Cell 10

11 Carcinoma of the Head and Neck: Results of a Phase I Dose-Escalation Trial. Int J Radiat Oncol Biol Phys, 75: 1493-500, 2009. 76) M.V. Karamouzis, P.A. Konstantinopoulos, A.G. Papavassiliou: Targeting c-met as a strategy to overcome cross-talk related resistance to EGFR protein -targeting agents in cancer therapeutics, Lancet Oncol, 10: 709-77, 2009. 77) A.G. Pallis, M.V. Karamouzis, P.A. Konstantinopoulos, A.G. Papavassiliou: Moleular networks in respiratory epithelium carcinomas, Cancer Lett, 95: 1-6, 2010. 78) I. Zachos, P.A. Konstantinopoulos, V. Tzortzis, S. Gravas, A. Karatzas, M.V. Karamouzis, M. Melekos, AG. Papavassiliou: Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise, Expert Opin Investig Drugs, 19: 875-87, 2010. 79) A. Kotsinas, I.S. Pateras, P.S. Galanos, M.V. Karamouzis, P.P. Sfikakis, V.G. Gorgoulis: Why is p53-inducible gene 3 rarely affected in cancer?, Oncogene, 29: 5220, 2010. 80) E.G. Iliopoulou, P. Kountourakis, M.V. Karamouzis, D. Doufexis, A. Ardavanis, C.N. Baxevanis, G. Rigatos,M. Papamichail, S.A. Perez: A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced nonsmall cell lung cancer, Cancer Immunol Immunother, 59: 1781-89, 2010. 81) A.G. Pallis, M.V. Karamouzis: DNA repair pathways and their implication in cancer treatment, Cancer Metastasis Rev, 29: 677-85, 2010. 82) Argiris, M.V. Karamouzis, W.E. Gooding, B.F. Branstetter, S. Zhong, L.E. Raez, P. Savvides, M. Romkes: Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer, J Clin Oncol, 29: 1140-45. 2011. 83) Argiris, M.V. Karamouzis: Empowering induction therapy for locally advanced head and neck cancer, Ann Oncol, 2010. 84) Argiris, M.V. Karamouzis, R. Smith, A. Kotsakis, M.K. Gibson, S.Y. La, S. Kim, B.F. Branstetter, Y. Shuai, M. Romkes, L. Wang, J.R. Grandis, R.L. Ferris, J.T. Johnson & D.E. Heron: Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer, Ann Oncol, 2011. 11

12 Τελευταία ενημέρωση : Μάρτιος 2011. 12